Amgen Inc. and Johnson & Johnson sell and market two very popular injectible anemia medicines. The FDA advisory panel has voted that Aranesp and Epogen, also known as Procrit, should have stronger warning labels. ESAs are approved to treat chemotherapy-induced anemia and chronic kidney disease-related anemia. The agency committee was meeting to reassess the risks of using of ESAs in the cancer...